Senaste publikationer
Publikationer
-
Combined quantitative tuberculosis biomarker model for time-to-positivity and colony forming unit to support tuberculosis drug development
Ingår i Frontiers in Pharmacology, 2023.
DOI för Combined quantitative tuberculosis biomarker model for time-to-positivity and colony forming unit to support tuberculosis drug development Ladda ner fulltext (pdf) av Combined quantitative tuberculosis biomarker model for time-to-positivity and colony forming unit to support tuberculosis drug development
-
Multistate Pharmacometric Model to Define the Impact of Second-Line Immunotherapies on the Survival Outcome of the IMpower131 Study
Ingår i Clinical Pharmacology and Therapeutics, s. 851-858, 2023.
DOI för Multistate Pharmacometric Model to Define the Impact of Second-Line Immunotherapies on the Survival Outcome of the IMpower131 Study Ladda ner fulltext (pdf) av Multistate Pharmacometric Model to Define the Impact of Second-Line Immunotherapies on the Survival Outcome of the IMpower131 Study
-
Optimization of blood pressure measurement practices for pharmacodynamic analyses of tyrosine-kinase inhibitors
Ingår i Clinical and Translational Science, s. 73-84, 2023.
DOI för Optimization of blood pressure measurement practices for pharmacodynamic analyses of tyrosine-kinase inhibitors Ladda ner fulltext (pdf) av Optimization of blood pressure measurement practices for pharmacodynamic analyses of tyrosine-kinase inhibitors
-
Rituximab pharmacokinetic and pharmacokinetic-pharmacodynamic evaluation based on a study in diffuse large B-cell lymphoma: Influence of tumor size on pharmacokinetic and assessment of pharmacokinetic similarity
Ingår i CPT, s. 154-167, 2023.
DOI för Rituximab pharmacokinetic and pharmacokinetic-pharmacodynamic evaluation based on a study in diffuse large B-cell lymphoma: Influence of tumor size on pharmacokinetic and assessment of pharmacokinetic similarity Ladda ner fulltext (pdf) av Rituximab pharmacokinetic and pharmacokinetic-pharmacodynamic evaluation based on a study in diffuse large B-cell lymphoma: Influence of tumor size on pharmacokinetic and assessment of pharmacokinetic similarity
-
Standards for model-based early bactericidal activity analysis and sample size determination in tuberculosis drug development
Ingår i Frontiers in Pharmacology, 2023.
DOI för Standards for model-based early bactericidal activity analysis and sample size determination in tuberculosis drug development Ladda ner fulltext (pdf) av Standards for model-based early bactericidal activity analysis and sample size determination in tuberculosis drug development
-
Model-based analysis of bactericidal activity and a new dosing strategy for optimised-dose rifampicin
Ingår i International Journal of Antimicrobial Agents, 2023.
DOI för Model-based analysis of bactericidal activity and a new dosing strategy for optimised-dose rifampicin Ladda ner fulltext (pdf) av Model-based analysis of bactericidal activity and a new dosing strategy for optimised-dose rifampicin
-
Clinical standards for the management of adverse effects during treatment for TB
Ingår i The International Journal of Tuberculosis and Lung Disease, s. 506-519, 2023.
DOI för Clinical standards for the management of adverse effects during treatment for TB Ladda ner fulltext (pdf) av Clinical standards for the management of adverse effects during treatment for TB
-
Predicting cytokine kinetics during sepsis; a modelling framework from a porcine sepsis model with live Escherichia coli
Ingår i Cytokine, 2023.
DOI för Predicting cytokine kinetics during sepsis; a modelling framework from a porcine sepsis model with live Escherichia coli Ladda ner fulltext (pdf) av Predicting cytokine kinetics during sepsis; a modelling framework from a porcine sepsis model with live Escherichia coli
-
Association between Sports Participation, Factor VIII Levels and Bleeding in Hemophilia A
Ingår i Thrombosis and Haemostasis, s. 317-325, 2023.
DOI för Association between Sports Participation, Factor VIII Levels and Bleeding in Hemophilia A Ladda ner fulltext (pdf) av Association between Sports Participation, Factor VIII Levels and Bleeding in Hemophilia A
-
Model-informed pediatric dose selection of marzeptacog alfa (activated): An exposure matching strategy
Ingår i CPT, s. 977-987, 2023.
DOI för Model-informed pediatric dose selection of marzeptacog alfa (activated): An exposure matching strategy Ladda ner fulltext (pdf) av Model-informed pediatric dose selection of marzeptacog alfa (activated): An exposure matching strategy
-
Model-Informed Support of Dose Selection for Prophylactic Treatment with Dalcinonacog Alfa in Adult and Paediatric Hemophilia B Patients
Ingår i Advances in Therapy, s. 3739-3750, 2023.
DOI för Model-Informed Support of Dose Selection for Prophylactic Treatment with Dalcinonacog Alfa in Adult and Paediatric Hemophilia B Patients Ladda ner fulltext (pdf) av Model-Informed Support of Dose Selection for Prophylactic Treatment with Dalcinonacog Alfa in Adult and Paediatric Hemophilia B Patients
-
Joint longitudinal model-based meta-analysis of FEV1 and exacerbation rate in randomized COPD trials
Ingår i Journal of Pharmacokinetics and Pharmacodynamics, s. 297-314, 2023.
DOI för Joint longitudinal model-based meta-analysis of FEV1 and exacerbation rate in randomized COPD trials Ladda ner fulltext (pdf) av Joint longitudinal model-based meta-analysis of FEV1 and exacerbation rate in randomized COPD trials
-
Large-scale WGS of carbapenem-resistant Acinetobacter baumannii isolates reveals patterns of dissemination of ST clades associated with antibiotic resistance
Ingår i Journal of Antimicrobial Chemotherapy, s. 934-943, 2022.
-
Model-Based Characterization of the Bidirectional Interaction Between Pharmacokinetics and Tumor Growth Dynamics in Patients with Metastatic Merkel Cell Carcinoma Treated with Avelumab
Ingår i Clinical Cancer Research, s. 1363-1371, 2022.
DOI för Model-Based Characterization of the Bidirectional Interaction Between Pharmacokinetics and Tumor Growth Dynamics in Patients with Metastatic Merkel Cell Carcinoma Treated with Avelumab Ladda ner fulltext (pdf) av Model-Based Characterization of the Bidirectional Interaction Between Pharmacokinetics and Tumor Growth Dynamics in Patients with Metastatic Merkel Cell Carcinoma Treated with Avelumab
-
Model-Informed Precision Dosing of Linezolid in Patients with Drug-Resistant Tuberculosis
Ingår i Pharmaceutics, 2022.
DOI för Model-Informed Precision Dosing of Linezolid in Patients with Drug-Resistant Tuberculosis Ladda ner fulltext (pdf) av Model-Informed Precision Dosing of Linezolid in Patients with Drug-Resistant Tuberculosis
-
Early Bactericidal Activity of Meropenem plus Clavulanate (with or without Rifampin) for Tuberculosis: The COMRADE Randomized, Phase 2A Clinical Trial
Ingår i American Journal of Respiratory and Critical Care Medicine, s. 1228-1235, 2022.
-
In vivo fitness of carbapenem-resistant Acinetobacter baumannii strains in murine infection is associated with treatment failure in human infections
Ingår i Clinical Microbiology and Infection, s. 73-78, 2022.
-
Pulmonary and systemic pharmacokinetics of colistin methanesulfonate (CMS) and formed colistin following nebulisation of CMS among patients with ventilator-associated pneumonia
Ingår i International Journal of Antimicrobial Agents, 2022.
-
Standard therapy of Mycobacterium avium complex pulmonary disease shows limited efficacy in an open source hollow fibre system that simulates human plasma and epithelial lining fluid pharmacokinetics
Ingår i Clinical Microbiology and Infection, s. 448.e1-448.e7, 2022.
DOI för Standard therapy of Mycobacterium avium complex pulmonary disease shows limited efficacy in an open source hollow fibre system that simulates human plasma and epithelial lining fluid pharmacokinetics Ladda ner fulltext (pdf) av Standard therapy of Mycobacterium avium complex pulmonary disease shows limited efficacy in an open source hollow fibre system that simulates human plasma and epithelial lining fluid pharmacokinetics
-
Finding the right hazard function for time-to-event modeling: A tutorial and Shiny application
Ingår i CPT, s. 991-1001, 2022.
DOI för Finding the right hazard function for time-to-event modeling: A tutorial and Shiny application Ladda ner fulltext (pdf) av Finding the right hazard function for time-to-event modeling: A tutorial and Shiny application
-
Improved Confidence in a Confirmatory Stage by Application of Item-Based Pharmacometrics Model: Illustration with a Phase III Active Comparator-Controlled Trial in COPD Patients
Ingår i Pharmaceutical research, s. 1779-1787, 2022.
DOI för Improved Confidence in a Confirmatory Stage by Application of Item-Based Pharmacometrics Model: Illustration with a Phase III Active Comparator-Controlled Trial in COPD Patients Ladda ner fulltext (pdf) av Improved Confidence in a Confirmatory Stage by Application of Item-Based Pharmacometrics Model: Illustration with a Phase III Active Comparator-Controlled Trial in COPD Patients
-
Machine Learning and Pharmacometrics for Prediction of Pharmacokinetic Data: Differences, Similarities and Challenges Illustrated with Rifampicin
Ingår i Pharmaceutics, 2022.
DOI för Machine Learning and Pharmacometrics for Prediction of Pharmacokinetic Data: Differences, Similarities and Challenges Illustrated with Rifampicin Ladda ner fulltext (pdf) av Machine Learning and Pharmacometrics for Prediction of Pharmacokinetic Data: Differences, Similarities and Challenges Illustrated with Rifampicin
-
Model-Informed Translation of In Vitro Effects of Short-, Prolonged- and Continuous-Infusion Meropenem against Pseudomonas aeruginosa to Clinical Settings
Ingår i Antibiotics, 2022.
DOI för Model-Informed Translation of In Vitro Effects of Short-, Prolonged- and Continuous-Infusion Meropenem against Pseudomonas aeruginosa to Clinical Settings Ladda ner fulltext (pdf) av Model-Informed Translation of In Vitro Effects of Short-, Prolonged- and Continuous-Infusion Meropenem against Pseudomonas aeruginosa to Clinical Settings
-
A modeling-based proposal for safe and efficacious reintroduction of bedaquiline after dose interruption: A population pharmacokinetics study
Ingår i CPT, s. 628-639, 2022.
DOI för A modeling-based proposal for safe and efficacious reintroduction of bedaquiline after dose interruption: A population pharmacokinetics study Ladda ner fulltext (pdf) av A modeling-based proposal for safe and efficacious reintroduction of bedaquiline after dose interruption: A population pharmacokinetics study
-
Anti-cancer treatment schedule optimization based on tumor dynamics modelling incorporating evolving resistance
Ingår i Scientific Reports, 2022.
DOI för Anti-cancer treatment schedule optimization based on tumor dynamics modelling incorporating evolving resistance Ladda ner fulltext (pdf) av Anti-cancer treatment schedule optimization based on tumor dynamics modelling incorporating evolving resistance
-
Population Pharmacokinetics and Exposure-Response Relationships of Astegolimab in Patients With Severe Asthma
Ingår i Journal of clinical pharmacology, s. 905-917, 2022.
DOI för Population Pharmacokinetics and Exposure-Response Relationships of Astegolimab in Patients With Severe Asthma Ladda ner fulltext (pdf) av Population Pharmacokinetics and Exposure-Response Relationships of Astegolimab in Patients With Severe Asthma
-
Predictive Modeling to Study the Treatment-Shortening Potential of Novel Tuberculosis Drug Regimens, Toward Bundling of Preclinical Data
Ingår i Journal of Infectious Diseases, s. 1876-1885, 2022.
DOI för Predictive Modeling to Study the Treatment-Shortening Potential of Novel Tuberculosis Drug Regimens, Toward Bundling of Preclinical Data Ladda ner fulltext (pdf) av Predictive Modeling to Study the Treatment-Shortening Potential of Novel Tuberculosis Drug Regimens, Toward Bundling of Preclinical Data
-
Population Pharmacokinetics of Flucloxacillin In Bone and Soft Tissue: Standard Dosing is Not Sufficient to Achieve Therapeutic Concentrations
Ingår i Pharmaceutical research, s. 1633-1643, 2022.
-
Expert workshop summary: Advancing toward a standardized murine model to evaluate treatments for antimicrobial resistance lung infections
Ingår i Frontiers in Microbiology, 2022.
DOI för Expert workshop summary: Advancing toward a standardized murine model to evaluate treatments for antimicrobial resistance lung infections Ladda ner fulltext (pdf) av Expert workshop summary: Advancing toward a standardized murine model to evaluate treatments for antimicrobial resistance lung infections
-
Translational in vitro and in vivo PKPD modelling for apramycin against Gram-negative lung pathogens to facilitate prediction of human efficacious dose in pneumonia
Ingår i Clinical Microbiology and Infection, s. 1367-1374, 2022.
DOI för Translational in vitro and in vivo PKPD modelling for apramycin against Gram-negative lung pathogens to facilitate prediction of human efficacious dose in pneumonia Ladda ner fulltext (pdf) av Translational in vitro and in vivo PKPD modelling for apramycin against Gram-negative lung pathogens to facilitate prediction of human efficacious dose in pneumonia
-
Population pharmacokinetics of apramycin from first-in-human plasma and urine data to support prediction of efficacious dose
Ingår i Journal of Antimicrobial Chemotherapy, s. 2718-2728, 2022.
DOI för Population pharmacokinetics of apramycin from first-in-human plasma and urine data to support prediction of efficacious dose Ladda ner fulltext (pdf) av Population pharmacokinetics of apramycin from first-in-human plasma and urine data to support prediction of efficacious dose
-
Research priorities towards precision antibiotic therapy to improve patient care
Ingår i LANCET MICROBE, s. e795-e802, 2022.
DOI för Research priorities towards precision antibiotic therapy to improve patient care Ladda ner fulltext (pdf) av Research priorities towards precision antibiotic therapy to improve patient care
-
Ceftriaxone dosing based on the predicted probability of augmented renal clearance in critically ill patients with pneumonia
Ingår i Journal of Antimicrobial Chemotherapy, s. 2479-2488, 2022.
-
Phase III dose selection of marzeptacog alfa (activated) informed by population pharmacokinetic modeling: A novel hemostatic drug
Ingår i CPT, s. 1628-1637, 2022.
DOI för Phase III dose selection of marzeptacog alfa (activated) informed by population pharmacokinetic modeling: A novel hemostatic drug Ladda ner fulltext (pdf) av Phase III dose selection of marzeptacog alfa (activated) informed by population pharmacokinetic modeling: A novel hemostatic drug
-
Pharmacometrics in tuberculosis: progress and opportunities
Ingår i International Journal of Antimicrobial Agents, 2022.
DOI för Pharmacometrics in tuberculosis: progress and opportunities Ladda ner fulltext (pdf) av Pharmacometrics in tuberculosis: progress and opportunities
-
Pharmacokinetic/pharmacodynamic models for time courses of antibiotic effects
Ingår i International Journal of Antimicrobial Agents, 2022.
DOI för Pharmacokinetic/pharmacodynamic models for time courses of antibiotic effects Ladda ner fulltext (pdf) av Pharmacokinetic/pharmacodynamic models for time courses of antibiotic effects
-
Safety and efficacy of BCG re-vaccination in relation to COVID-19 morbidity in healthcare workers: A double- blind, randomised, controlled, phase 3 trial
Ingår i eClinicalMedicine, 2022.
DOI för Safety and efficacy of BCG re-vaccination in relation to COVID-19 morbidity in healthcare workers: A double- blind, randomised, controlled, phase 3 trial Ladda ner fulltext (pdf) av Safety and efficacy of BCG re-vaccination in relation to COVID-19 morbidity in healthcare workers: A double- blind, randomised, controlled, phase 3 trial
-
Study protocol for locoregional precision treatment of hepatocellular carcinoma with transarterial chemoembolisation (TACTida), a clinical study: idarubicin dose selection, tissue response and survival
Ingår i BMJ Open, 2022.
DOI för Study protocol for locoregional precision treatment of hepatocellular carcinoma with transarterial chemoembolisation (TACTida), a clinical study: idarubicin dose selection, tissue response and survival Ladda ner fulltext (pdf) av Study protocol for locoregional precision treatment of hepatocellular carcinoma with transarterial chemoembolisation (TACTida), a clinical study: idarubicin dose selection, tissue response and survival
-
Safety and pharmacokinetics-pharmacodynamics of a shorter tuberculosis treatment with high-dose pyrazinamide and rifampicin: a study protocol of a phase II clinical trial (HighShort-RP)
Ingår i BMJ Open, 2022.
DOI för Safety and pharmacokinetics-pharmacodynamics of a shorter tuberculosis treatment with high-dose pyrazinamide and rifampicin: a study protocol of a phase II clinical trial (HighShort-RP) Ladda ner fulltext (pdf) av Safety and pharmacokinetics-pharmacodynamics of a shorter tuberculosis treatment with high-dose pyrazinamide and rifampicin: a study protocol of a phase II clinical trial (HighShort-RP)
-
A Time-to-Event Model Relating Integrated Craving to Risk of Smoking Relapse Across Different Nicotine Replacement Therapy Formulations
Ingår i Clinical Pharmacology and Therapeutics, s. 416-423, 2021.
-
Model-Informed Drug Development for Anti-Infectives: State of the Art and Future
Ingår i Clinical Pharmacology and Therapeutics, s. 867-891, 2021.
DOI för Model-Informed Drug Development for Anti-Infectives: State of the Art and Future Ladda ner fulltext (pdf) av Model-Informed Drug Development for Anti-Infectives: State of the Art and Future
-
Excluded versus included patients in a randomized controlled trial of infections caused by carbapenem-resistant Gram-negative bacteria: relevance to external validity
Ingår i BMC Infectious Diseases, 2021.
DOI för Excluded versus included patients in a randomized controlled trial of infections caused by carbapenem-resistant Gram-negative bacteria: relevance to external validity Ladda ner fulltext (pdf) av Excluded versus included patients in a randomized controlled trial of infections caused by carbapenem-resistant Gram-negative bacteria: relevance to external validity
-
Pharmacometrics-Based Considerations for the Design of a Pharmacogenomic Clinical Trial Assessing Irinotecan Safety
Ingår i Pharmaceutical research, s. 593-605, 2021.
DOI för Pharmacometrics-Based Considerations for the Design of a Pharmacogenomic Clinical Trial Assessing Irinotecan Safety Ladda ner fulltext (pdf) av Pharmacometrics-Based Considerations for the Design of a Pharmacogenomic Clinical Trial Assessing Irinotecan Safety
-
CPT: Pharmacometrics & Systems Pharmacology - Inception, Maturation, and Future Vision
Ingår i CPT, s. 649-657, 2021.
DOI för CPT: Pharmacometrics & Systems Pharmacology - Inception, Maturation, and Future Vision Ladda ner fulltext (pdf) av CPT: Pharmacometrics & Systems Pharmacology - Inception, Maturation, and Future Vision
-
Pivotal Role of Translation in Anti-Infective Development
Ingår i Clinical Pharmacology and Therapeutics, s. 856-866, 2021.
DOI för Pivotal Role of Translation in Anti-Infective Development Ladda ner fulltext (pdf) av Pivotal Role of Translation in Anti-Infective Development
-
Model-Informed Drug Development for Antimicrobials: Translational PK and PK/PD Modeling to Predict an Efficacious Human Dose for Apramycin
Ingår i Clinical Pharmacology and Therapeutics, s. 1063-1073, 2021.
DOI för Model-Informed Drug Development for Antimicrobials: Translational PK and PK/PD Modeling to Predict an Efficacious Human Dose for Apramycin Ladda ner fulltext (pdf) av Model-Informed Drug Development for Antimicrobials: Translational PK and PK/PD Modeling to Predict an Efficacious Human Dose for Apramycin
-
Suboptimal moxifloxacin and levofloxacin drug exposure during treatment of patients with multidrug-resistant tuberculosis: results from a prospective study in China.
Ingår i European Respiratory Journal, 2021.
-
Efficacy of EBL-1003 (apramycin) against Acinetobacter baumannii lung infections in mice
Ingår i Clinical Microbiology and Infection, s. 1315-1321, 2021.
DOI för Efficacy of EBL-1003 (apramycin) against Acinetobacter baumannii lung infections in mice Ladda ner fulltext (pdf) av Efficacy of EBL-1003 (apramycin) against Acinetobacter baumannii lung infections in mice